| Literature DB >> 30300580 |
William B Tu1, Yu-Jia Shiah2, Corey Lourenco1, Peter J Mullen3, Dharmendra Dingar3, Cornelia Redel1, Aaliya Tamachi3, Wail Ba-Alawi1, Ahmed Aman4, Rima Al-Awar5, David W Cescon6, Benjamin Haibe-Kains1, Cheryl H Arrowsmith7, Brian Raught1, Paul C Boutros8, Linda Z Penn9.
Abstract
MYC is an oncogenic driver that regulates transcriptional activation and repression. Surprisingly, mechanisms by which MYC promotes malignant transformation remain unclear. We demonstrate that MYC interacts with the G9a H3K9-methyltransferase complex to control transcriptional repression. Inhibiting G9a hinders MYC chromatin binding at MYC-repressed genes and de-represses gene expression. By identifying the MYC box II region as essential for MYC-G9a interaction, a long-standing missing link between MYC transformation and gene repression is unveiled. Across breast cancer cell lines, the anti-proliferative response to G9a pharmacological inhibition correlates with MYC sensitivity and gene signatures. Consistently, genetically depleting G9a in vivo suppresses MYC-dependent tumor growth. These findings unveil G9a as an epigenetic regulator of MYC transcriptional repression and a therapeutic vulnerability in MYC-driven cancers.Entities:
Keywords: BioID; G9a; MYC; breast cancer; epigenetic therapy; histone methylation; transcriptional repression
Mesh:
Substances:
Year: 2018 PMID: 30300580 DOI: 10.1016/j.ccell.2018.09.001
Source DB: PubMed Journal: Cancer Cell ISSN: 1535-6108 Impact factor: 31.743